Forensic Analysis · Consumer Staples / Food & Beverage · as of Aug 11, 2026
Sanfilippo John B & Son Inc (JBSS)
A forensic read on Sanfilippo John B & Son Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
8.5
Distress distance
Clean
Earnings quality
5
Forensic signals
14.5
P / E (ttm)
16.3%
ROE
$962M
Market cap
1.14%
Dividend yield
3.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Sanfilippo John B & Son Inc earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 8.5, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
91d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 79 to 91 FY2024→FY2025 (against cost of goods sold; inventory +30% vs +6% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
FCF ($20M)
FY2025
Shareholder returns.Returned $24M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($20M) after capex — there was no free cash flow to fund the payout from at all, though operating cash flow alone was $31M — 80% of that. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
+13.2%
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets grew +13.2% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building faster than is comfortable — part of profit is sitting in the balance sheet rather than turning to cash. The build is led by inventory up +30% against +6% in cost of sales. The cash-flow cross-check agrees: reported earnings ran ahead of operating cash by 8% of net operating assets.
+0.4%/yr
FY2022–FY2025
Share count.Diluted share count changed +1% over the last 3 years to FY2025 (+0.4%/yr). Roughly flat — the count is neither shrinking nor growing meaningfully. Per-share value isn't being meaningfully helped or hurt by the count.
-50%
Key fundamentals
Latest Revenue$1.11B
Revenue Growth YoY+3.8%
Revenue CAGR (3yr)+5.0%
Net Margin5.3%
Free Cash Flow-$20.2M
Return on Equity16.3%
Debt / Equity0.04x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Sanfilippo John B & Son Inc's actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Aug 11, 2026. Forensic signals flag probability, not certainty.
Sanfilippo John B & Son Inc (JBSS) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
FY2017→FY2018
Dividend — cut.The payout was CUT ~50% in FY2018 (from FY2017) and hasn't been restored since. It still returns some cash, but it is NOT the dependable, rising dividend an unbroken streak implies.